Cancer, Hyperthermia
Conditions
Keywords
Hyperthermia E02.565, HTRegister
Brief summary
This monocentric study registry records all cancer patients at the Charité which are treated with hyperthermia to examine the therapeutic use of hyperthermia in cancer patients in the general application and to obtain an accurate risk-benefit balance After confinement in this database are the patients prospectively in order to complications, disease status and survival status tracked. Furthermore there is the possibility in the course of this study to an optional take part in translational accompanying research with the aim of prognostic factors for response to hyperthermia treatment.
Detailed description
A total of 1000 patients with various diseases with the indication for hyperthermia in addition to standard oncological therapy (radiation therapy, chemotherapy, radiochemotherapy) will be included in this registry protocol.
Interventions
OTHERHyperthermie Register
* die Höhe der Temperatur im Zielgebiet (42,5 bis 43 °C), * die Dauer der Anwendung und * die simultane Therapie mit Chemo- und/oder Strahlentherapie
Sponsors
Pirus Ghadjar
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Contrazeption with female patients at the capable of bearing children age * Written agreement is present (DvH, ICH-GCP) * Patients, who participate at the same time in a interventional study, can nevertheless in this register study participate if this none Exclusion criterion for the interventional study represents. * With children must the treatment with one of the GPOH agreed Pattern take place
Exclusion criteria
*
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effectivity | Through the study completion, up to 10 years | To determine the effectiveness of hyperthermia treatment, patients are tracked in terms of overall survival , progression-free survival and disease-free survival |
| Toxicity | Through the study completion, up to 10 years | Toxicity assessment based on Common Toxicity Criteria Scoring |
Countries
Germany
Contacts
Primary ContactPirus Ghadjar, PD Dr.
Outcome results
None listed